HIV Infections, Pregnancy, HIV Seronegativity
Conditions
Keywords
Vaccines, Synthetic, Pregnancy, Pregnancy Complications, Infectious, HIV Envelope Protein gp160, AIDS Vaccines, HIV Preventive Vaccine, HIV Therapeutic Vaccine
Brief summary
To evaluate the safety of gp160 vaccine (VaxSyn) in HIV-1 infected pregnant women with CD4 counts \>= 400 cells/mm3. To evaluate the immunogenicity of this vaccine in pregnant women and the passive acquisition of vaccine-specific antibody in their infants. Evidence suggests that an advanced stage of disease with high plasma viremia is associated with increased transmission of HIV-1 to the fetus. Slowing the progression of disease, reducing the titer of virus in plasma, and increasing the titer of epitope-specific antibody are potentially attainable goals through active immunization of the mother during pregnancy.
Detailed description
Evidence suggests that an advanced stage of disease with high plasma viremia is associated with increased transmission of HIV-1 to the fetus. Slowing the progression of disease, reducing the titer of virus in plasma, and increasing the titer of epitope-specific antibody are potentially attainable goals through active immunization of the mother during pregnancy. Pregnant women are randomized to receive an initial injection of VaxSyn or alum placebo between week 16 and week 24 of gestation, followed by monthly booster injections concluding at the end of pregnancy, for a total of five injections. Patients may have optional booster immunizations (vaccine or placebo) at 3, 6, 9, and 12 months after delivery. Mothers and infants are followed through 18 months after delivery.
Interventions
BIOLOGICALgp160 Vaccine (MicroGeneSys)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Intervention model
PARALLEL
Primary purpose
TREATMENT
Eligibility
Sex/Gender
FEMALE
Age
16 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
Concurrent Medication: Allowed: * AZT. * Acyclovir. Patients must have: * HIV-1 infection. * CD4 count \>= 400 cells/mm3. * No AIDS-defining illness or other systemic manifestations related to HIV (other than generalized lymphadenopathy). * HIV p24 \< 30 pg/ml. * Proven pregnancy in the 16th to 24th week of gestation at study entry, with no special obstetrical risks. * Concurrent AZT therapy is permitted.
Exclusion criteria
Co-existing Condition: Patients with the following symptoms and conditions are excluded: * Known hypersensitivity to a component of the vaccine. * Evidence of fetal abnormality on ultrasound. * Evidence of maternal risk factors including insulin-dependent diabetes, moderate to severe hypertension, repeated fetal wastage (\> 3), Rh-sensitization or other blood group alloimmunization, severe renal disease, previous infants with malformations or other factors that obstetrically are judged to constitute a special risk of spontaneous abortion or premature birth. * Active syphilis. * Hepatitis B surface antigen positive. Concurrent Medication: Excluded: * Antiretroviral or immunomodulating agent other than AZT during the pregnancy. Prior Medication: Excluded: * Antiretroviral or immunomodulating agent other than AZT within 90 days prior to study entry. Current use of illicit drugs or known chronic alcohol use.
Countries
United States
Outcome results
None listed